Exabis Library
Welcome to the e-CCO Library!
P589 Longer-term outcomes in patients with Crohn’s disease who are primary non-responders to anti-TNF in a single UK centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P589: A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P589: Adherence to medical treatment in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P589: Effectiveness of partial enteral nutrition to treat adults with Crohn's Disease who lost response to biological therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P589: Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P589: Stable Trends in Radiation Exposure Amongst Patients with a New Diagnosis of Inflammatory Bowel Disease at an Irish Tertiary Referral Hospital
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P589: Total thiopurine exposure and impact on the development of keratinocyte carcinomas in Inflammatory Bowel Disease patients; a case control study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P590 Outcomes of patients treated with sequential anti-TNF therapy in a tertiary referral centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P590: ADVANCED-UC TRIAL: AppenDectomy Vs ANti TNF-a in inducing Clinical and EnDoscopic remission in left-sided Ulcerative Colitis – A Randomized Clinical Trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P590: Laparoscopy in Crohn’s disease: Learning curve and current practice
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P590: Reasons for discontinuation and switch of biologic therapy in IBD: findings from a large international observational study (03)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P590: Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panel
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P590: Which biomarkers have an effect on therapeutic vedolizumab drug levels? A retrospective analysis from a London Tertiary Centre.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P591 Therapeutic management in inflammatory bowel disease: Differences in two IBD inception cohorts: 1991–93 and 2010–11 enrolled in the north-west of Spain
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P591: Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national multicentric study from the Brazilian Study Group of IBD (GEDIIB).
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P591: Biological therapies and small molecules show to be efficacious in patients with moderate-to-severe ulcerative proctitis.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P591: Gastroenterologist performed point-of-care gastrointestinal ultrasound improves patient understanding of disease activity, symptomatology, management decisions and clinical outcomes
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P591: Low donor microbial engraftment after combined endoscopic and oral faecal microbiota transplant (FMT) in patients with antibiotic dependent pouchitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P591: Negative impact of high body mass index on the efficacy of anti-TNFα agents in patients with Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P591: Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approach
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM